Investing in Crinetics Pharmaceuticals, Inc. (CRNX)  ➔  Intrinsic value

Prev. close$22.80 
ModelValueUpside
Chepakovich$4.64-80%
Graham-Dodd$0.00-100%
Graham$163.86+619%
Previous Close$22.80  
Valuation MethodValuePotential 
Chepakovich Model$4.64-80%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$163.86+619%recalculate

Latest news

Company description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.